読み込み中
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
前日終値
$1.44
−$0.02 · -1.37%
日中の時刻はETです。市場データは遅延する場合があります。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日中レンジ
現在 $1.44
52週レンジ
現在 $1.44
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
56
まちまち
リスク
66
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日中レンジ
現在 $1.44
52週レンジ
現在 $1.44
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 373.1万 USD | 762万 USD | 1703.4万 USD | 1632万 USD | 1182.7万 USD |
| 販売・一般管理 | 298.3万 USD | 293.5万 USD | 484.4万 USD | 596.2万 USD | 582.1万 USD |
| 営業費用 | 2745.8万 USD | 1100.5万 USD | 2227.1万 USD | 2260.3万 USD | 1793.4万 USD |
| 受取利息 | 22.7万 USD | 26万 USD | 47.4万 USD | 53.2万 USD | 32万 USD |
| 支払利息 | 3.9万 USD | 4.1万 USD | 5.6万 USD | 6.7万 USD | 7.9万 USD |
| 減価償却費と償却費 | 20.3万 USD | 18.6万 USD | 19.7万 USD | 20.1万 USD | 23.1万 USD |
| 営業利益 | −2745.8万 USD | −1100.5万 USD | −2227.1万 USD | −2260.3万 USD | −1793.4万 USD |
| 純利益 | −2638.6万 USD | −724万 USD | −1988万 USD | −2166.8万 USD | −1838.4万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
